ArticleEuropean journal of medical research2025
The potential of MCM8 as a biomarker in esophageal carcinoma: a comprehensive analysis integrating m6a methylation and angiogenesis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SQLE as a potential diagnostic and prognostic biomarker for LIHC: a multi-cohort and spatial study.NPJ precision oncology · 2026Article
- Integrative genomic and functional analysis of RAB3B in lung adenocarcinoma: associations with m6A modification and ceRNA networks.Frontiers in pharmacology · 2026Article
- Epigenetic regulation of TNNT1 in gastrointestinal cancers prognostic implications and clinical significance.Clinical epigenetics · 2025Article
- Integrated multi-omics analysis of UL16-binding protein 2 as a prognostic and immunotherapy biomarker for colorectal cancer.Functional & integrative genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective biomarkers for esophageal carcinoma (ESCA) are currently lacking. Here, we examined the role of minichromosome maintenance complex component 8 (MCM8) as a diagnostic and prognostic marker in ESCA and its association with m6a methylation and angiogenesis, and constructed a competing endogenous RNA (ceRNA) network.
methodsClinical data and gene expression profiles were obtained from The Cancer Genome Atlas and Gene Expression Omnibus datasets. Differential gene expression analysis was performed using DESeq2 and limma packages. The prognostic significance of MCM8 expression regarding overall survival (OS) was examined using the Cox proportional hazards model. Receiver Operating Characteristic (ROC) analysis was used to assess the diagnostic potential of MCM8. MCM8 expression in ESCA tissues was evaluated by immunohistochemical staining on a tissue microarray. Pearson correlation analysis identified co-expressed genes, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. The GEPIA online tool was used to examine the relationship between MCM8 and m6a methylation as well as angiogenesis-related genes. MicroRNA and long noncoding RNA predictions were made using miRWalk, MicroT-CDS, ENCORI, and miRNet tools to construct the ceRNA network.
resultsMCM8 was significantly overexpressed in tumor tissues and showed high diagnostic accuracy in the ROC analysis with an area under the curve of 0.920. Kaplan-Meier survival analysis revealed that high MCM8 expression correlated with poorer OS and disease-specific survival. Pearson correlation analysis identified a significant correlation between MCM8 and several m6a methylation-related genes such as HNRNPA2B1 and YTHDF1, as well as PTK2, an angiogenesis-related gene. A ceRNA network including MCM8, PURPL/hsa-miR- 135a- 5p/MCM8 was successfully predicted and constructed.
conclusionsMCM8 is a promising biomarker in ESCA and it is associated with m6a methylation and angiogenesis, showing potential as a therapeutic target. The ceRNA network provided insight into the pathogenesis of ESCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.